Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

BioZorb Markers and Twin Tubes Get Recalls Designated Class I

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

Hologic BioZorb Markers with excessive adverse event reports and Vyaire Medical’s Twin Tube with the potential for the nozzle separating during patient use have been deemed as Class I recalls…

Continue ReadingBioZorb Markers and Twin Tubes Get Recalls Designated Class I

CDER Science, Research Efforts that Support Generics Detailed in 2023 Annual Report

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

The collaborative efforts that advance the development of more generic drugs is the work of CDER’s science and research program whose 2023 annual report provides details on the efforts behind…

Continue ReadingCDER Science, Research Efforts that Support Generics Detailed in 2023 Annual Report

Regulatory Update — Week of May 20, 2024

  • Post author:PacConAdmin
  • Post published:May 24, 2024
  • Post category:Uncategorized

This week, the FDA issued a final rule reclassifying ultrasound cyclodestructive devices and published a notice seeking nominations for advisory panels of the Medical Devices Advisory Committee. Source: Drug Industry…

Continue ReadingRegulatory Update — Week of May 20, 2024

DC Circuit Upholds Ruling Allowing Drugmakers to Restrict Deliveries to Contract Pharmacies

  • Post author:PacConAdmin
  • Post published:May 23, 2024
  • Post category:Uncategorized

A federal appeals court has upheld a lower court ruling that the controversial 340B Drug Discount Program doesn’t stop drugmakers from restricting deliveries of discounted drugs to contract pharmacies. Source:…

Continue ReadingDC Circuit Upholds Ruling Allowing Drugmakers to Restrict Deliveries to Contract Pharmacies

BMS, Sanofi Owe $916M After Hawaii Retrial Over Plavix

  • Post author:PacConAdmin
  • Post published:May 23, 2024
  • Post category:Uncategorized

Bristol Myers Squibb (BMS) and three US subsidiaries of Paris-based Sanofi owe the state of Hawaii a combined $916 million over safety disclosure failures with blood-thinning drug Plavix, following a…

Continue ReadingBMS, Sanofi Owe $916M After Hawaii Retrial Over Plavix

AdComm Must Balance Benefit of Once-Weekly Insulin with Risk of Severe Hypoglycemia

  • Post author:PacConAdmin
  • Post published:May 23, 2024
  • Post category:Uncategorized

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will attempt to balance the benefits of Novo Nordisk’s once-weekly insulin injection Awiqli with an increased risk of moderate and severe hypoglycemia…

Continue ReadingAdComm Must Balance Benefit of Once-Weekly Insulin with Risk of Severe Hypoglycemia

Lawmakers Question, Chide FDA Leaders at Congressional Hearing

  • Post author:PacConAdmin
  • Post published:May 23, 2024
  • Post category:Uncategorized

Drug shortages, patent tussles, and gripes about the Inflation Reduction Act (IRA) headlined the conversation at an FDA “check-up” meeting conducted by the House Energy and Commerce’s subcommittee on health.…

Continue ReadingLawmakers Question, Chide FDA Leaders at Congressional Hearing

Where Companies Go Wrong in Responses to FDA Form 483 Inspection Observations

  • Post author:PacConAdmin
  • Post published:May 22, 2024
  • Post category:Uncategorized

One of the biggest mistakes companies make in their responses to the FDA’s inspection observations is to focus on the specific issues raised without looking at the bigger picture, according…

Continue ReadingWhere Companies Go Wrong in Responses to FDA Form 483 Inspection Observations

NIH Proposes Patent Agreements With Partners Who Receive Their Funding

  • Post author:PacConAdmin
  • Post published:May 22, 2024
  • Post category:Uncategorized

NIH is seeking comments on a new policy that would require partnering organizations who receive institute funding to submit a plan outlining steps they will take — through a patent…

Continue ReadingNIH Proposes Patent Agreements With Partners Who Receive Their Funding

Magellan Diagnostics Agrees to Plead Guilty, Pay $42 Million

  • Post author:PacConAdmin
  • Post published:May 22, 2024
  • Post category:Uncategorized

Magellan Diagnostics has agreed to plead guilty and pay $42 million for concealing a device malfunction for years that produced inaccurately low lead test results for potentially tens of thousands…

Continue ReadingMagellan Diagnostics Agrees to Plead Guilty, Pay $42 Million
  • Go to the previous page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company